日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Functional analysis of pathogenic variants in LAMB1-related leukoencephalopathy reveals genotype-phenotype correlations and suggests its role in glial cells.

LAMB1相关脑白质病致病变异的功能分析揭示了基因型-表型相关性,并表明其在神经胶质细胞中的作用

Yasuda Rei, Hashimoto Hirokazu, Oka Mikiko, Mok Jung-Wan, Waqar Marium, Dauwalder Brigitte, Kanca Oguz, Mizuno Toshiki, Yamamoto Shinya

TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X

TAS-121 是一种选择性突变型 EGFR 抑制剂,对表达各种 EGFR 突变(包括 T790M 和罕见突变 G719X)的肿瘤具有活性

Kimihiro Ito, Makoto Nishio, Masanori Kato, Haruyasu Murakami, Yoshimi Aoyagi, Yuichiro Ohe, Takashige Okayama, Akihiro Hashimoto, Hirokazu Ohsawa, Gotaro Tanaka, Katsumasa Nonoshita, Satoru Ito, Kenichi Matsuo, Kazutaka Miyadera

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

TAS0728,一种共价结合的 HER2 选择性激酶抑制剂,在临床前模型中表现出强大的抗肿瘤活性

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo

P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance

P53 和甲羟戊酸通路驱动的恶性肿瘤需要 Arf6 来实现转移和耐药性

Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto, Hirokazu Sugino, Ayumu Yoshikawa, Yutaro Otsuka, Haruka Handa, Yasuhito Onodera, Jin-Min Nam, Chitose Oneyama, Masato Okada, Mitsunori Fukuda, Hisataka Sabe

Organotypic coculture preparation for the study of developmental synapse elimination in mammalian brain

用于研究哺乳动物大脑发育突触消除的器官型共培养制剂

Naofumi Uesaka, Takayasu Mikuni, Kouichi Hashimoto, Hirokazu Hirai, Kenji Sakimura, Masanobu Kano